Compare Bristol-Myers Squibb Co (BMY) vs iShares 3 7 Year Treasury Bond ETF (IEI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs iShares 3 7 Year Treasury Bond ETF — how do they compare? Bristol-Myers Squibb Co trades at $63.69 (market cap $129.94B), while iShares 3 7 Year Treasury Bond ETF trades at $116.45. The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while iShares 3 7 Year Treasury Bond ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, iShares 3 7 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| BMY | IEI | |
|---|---|---|
Market Cap | $129.94B | — |
Sector | Health | Fixed Income |
52-Week High | $65.89 | $120.72 |
52-Week Low | $42.60 | $116.16 |
Enterprise Value | $163.92B | — |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
IEI, the iShares 3-7 Year Treasury Bond ETF, trades at $116.46, up 0.18% today, with a bearish technical signal from moving averages and neutral oscillators. The ETF has paid recent dividends, including $0.38 per share in July 2026. News highlights focus on Treasury yield volatility amid inflation data and geopolitical tensions, influencing bond market sentiment.
Outlook is cautious due to bearish technicals and rising yield pressures. Opportunities include government backing and income from dividends, but risks involve Fed rate hike expectations and oil-driven inflation. Investors face volatility from macroeconomic shifts and bond market reactions to policy changes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About iShares 3 7 Year Treasury Bond ETF
IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.
Read more on IEI →
